TOKYO/LONDON – The government has reached a deal to have Pfizer Inc. and BioNTech SE supply 120 million doses of a coronavirus vaccine to Japan by the end of June 2021, if the medicine proves effective.
The supply from the U.S. pharmaceutical giant and its German partner is enough to treat 60 million people.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.